Business Wire

Sabesp Delivers 92,000 Smart Water Meters Powered by the Sigfox 0G Network Operated by WND in Brazil

19.5.2021 10:35:00 EEST | Business Wire | Press release

Share

Sabesp, one of the largest water and sewage service providers in the world, today announces that it has successfully completed the implementation of 100,000 smart water meters with Internet of Things (IoT) technology. The project, which is one of the largest in Latin America, introduces water consumption telemeasurement in Sabesp's 100,000 largest consumers in the Metropolitan Region of São Paulo.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210519005356/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sabesp smart water meters (Photo: Sigfox)

The Metrolink consortium is delivering the project and comprises of companies Laager and Vita Ambiental, which won the contract after a competitive bidding process Sabesp started at the end of 2018.

WND's Sigfox 0G network was the communication technology selected by Sabesp for more than 92,000 of the total connected water meters. WND is the exclusive operator of Sigfox technology in Brazil. Sigfox technology enables the transport of data wirelessly, at low cost, over long distances, with minimum energy consumption. The devices will be in operation for at least five years without changing or recharging the battery.

Telemetering – the remote reading of meters – automates the process of measuring water consumption. The task was performed manually once a month and can now be performed multiple times a day. In addition to measurement, the system also generates alarms and important statistics about the operation of the entire water network. All of these new features bring reliability, transparency and savings to consumers and unprecedented operational efficiency for Sabesp.

Ricardo Batista, Sabesp's Division Manager and responsible for the project, comments: "The project marked the large-scale adoption of the IoT concept by Sabesp. The new technology enables our customers to monitor water consumption daily, as well as leak detection, saving money and preserving the environment, in addition to better management of resources by our company. We hope to be able to expand the project in the coming years."

According to Felipe Duque Estrada, CEO of Laager, the success of the project is largely due to the partnership with Sigfox and WND Brazil: "The adoption of 0G network technologies from Sigfox ensured the economic and technological viability of the project."

José Almeida, Deputy CEO of WND Brazil, adds: "Thanks to Sabesp's pioneering approach, Laager's expertise and our work together, we have delivered one of the largest IoT projects in the Americas. The results achieved demonstrate, without any doubt, that our technology and business model are the best choices for IoT projects today."

Carlos Beato, VP Americas at Sigfox concludes: “We are incredibly proud of SABESP’s achievement and visionary take on smart water metering. The benefits of such a solution go far beyond remote reading. It truly transforms the customer experience and Quality of Service.

*****

Sabesp – Companhia de Saneamento Básico do Estado de São Paulo (http://www.sabesp.com.br/) is the largest sanitation company in the Americas and the fourth largest in the world in the population served. It is responsible for the supply of water, sewage collection and treatment in 375 municipalities in the State of São Paulo, besides representing 30% of the investment in basic sanitation made in Brazil.

Laager Tecnologias Sustentáveis Ltda is a company specialized in technological solutions aimed at sustainability. Its devices make it possible to control the consumption of water, gas and electricity, besides allowing greater efficiency in consumption. The company has an advanced system of individualization of these resources, which can be applied to small, medium and large consumers.

Vita Ambiental is a traditional specialized Engineering Services provider for sanitation companies, focusing on reducing losses and operational optimizations.

WND Brazil, which is part of the WND Group (https://www.wndgroup.io/), operates in the IoT (Internet of Things) market through the implementation of a national public network, in a B2B (Business to Business) model that allows the sale of connectivity at low cost. In just three years of operation in Brazilian territory, the company is already present in all capital cities of the country, covering an area with a population of more than 120 million inhabitants and serving more than 360 cities. WND Brazil is a pioneer in a national public network dedicated exclusively to IoT using Sigfox technology.

Sigfox is the 0G network pioneer and the world’s leading IoT (Internet of Things) service provider. Sigfox offers a unique combination of ultra-low cost and ultra-low power technologies supported by a global network, enabling businesses to gain visibility and track their assets worldwide. With more than 17 million connected devices and 70 million messages sent a day, Sigfox helps its customers to extract crucial data at the lowest cost and to accelerate their digital transformation in key areas such as Asset Tracking and Supply Chain.

ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox was founded in 2010 and is headquartered in Labège, France, with offices in Boston, Dallas, Dubai, Madrid, Paris, Sao Paulo, Singapore and Tokyo.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sigfox
Antoine Mège, PR & Content Manager
antoine.mege@sigfox.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release

Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release

Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas

Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye